NASAMissions
Accelerating CSC discoveries through NASA-funded low-Earth orbit experiments
Breaking Barriers
Unmasking cancer’shidden defenses to endrelapse at its root.
About Aspera
Pioneering OncologyFrom Orbit to Clinic
At Aspera Biomedicines, we are pioneering cancer stem cell therapy. Our approach, supported by NASA-funded low-Earth orbit research, revolutionizes oncology and regenerative medicine by targeting cancer stem cells (CSCs) that drive relapse and metastasis.
Our lead asset, Rebecsinib—a first-in-class inhibitor of oncogenic ADAR1 expression—blocks malignant regeneration and immune evasion in over 20 cancers, accelerated by groundbreaking low-Earth orbit research.
The Science
Micro-Gravity RevealsWhat Gravity Hides
In microgravity, cancer stem cells are stress-tested under conditions impossible to replicate on Earth. Tumors adapt up to seven times faster, revealing relapse biology and drug resistance mechanisms that guide our pipeline.
Each mission compresses years of disease evolution into days using our proprietary nanobioreactor platforms. Validated across 10 ISS missions, targeting the “dark genome” for precision therapies.
Pipeline
Rebecsinib
ADAR p150 Inhibitor // First-in-Class
Phases 1 & 2 Active
20+
Cancers Targeted
MF
Myelofibrosis
sAML
Secondary Acute Myeloid Leukemia
1st
FDA-Cleared ADAR1
Advancing the Frontierof Cancer Medicine
Discover how space-accelerated research is transforming cancer therapy.